Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q36838375)
Watch
English
Chemotherapy for prostate cancer: Clinical practice in Canada.
scientific article published on January 2013
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
3652211
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682304%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
title
Chemotherapy for prostate cancer: Clinical practice in Canada
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
3652211
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682304%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
main subject
Canada
0 references
prostate cancer
1 reference
based on heuristic
inferred from title
author
Fred Saad
series ordinal
1
object named as
Fred Saad
1 reference
stated in
Europe PubMed Central
PMC publication ID
3652211
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682304%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
author name string
Jamil Asselah
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
3652211
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682304%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
publication date
1 January 2013
1 reference
stated in
Europe PubMed Central
PMC publication ID
3652211
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682304%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
published in
Canadian Urological Association journal
1 reference
stated in
Europe PubMed Central
PMC publication ID
3652211
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682304%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
volume
7
1 reference
stated in
Europe PubMed Central
PMC publication ID
3652211
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682304%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
issue
1-2 Suppl 1
1 reference
stated in
Europe PubMed Central
PMC publication ID
3652211
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682304%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
page(s)
S5-S10
1 reference
stated in
Europe PubMed Central
PMC publication ID
3652211
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682304%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
cites work
Optimal management of patients receiving cabazitaxel-based chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652211
retrieved
29 September 2017
Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652211
retrieved
29 September 2017
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652211
retrieved
29 September 2017
Guidelines for the management of castrate-resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652211
retrieved
29 September 2017
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652211
retrieved
29 September 2017
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652211
retrieved
29 September 2017
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652211
retrieved
29 September 2017
Cabazitaxel in prostate cancer: stretching a string
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652211
retrieved
5 September 2018
What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652211
retrieved
5 September 2018
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652211
retrieved
5 September 2018
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652211
retrieved
5 September 2018
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652211
retrieved
5 September 2018
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652211
retrieved
5 September 2018
The impact of cross-resistance between paclitaxel and docetaxel for metastatic gastric cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23682304
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.5489/CUAJ.273
1 reference
stated in
Europe PubMed Central
PMC publication ID
3652211
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682304%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
PMC publication ID
3652211
1 reference
stated in
Europe PubMed Central
PMC publication ID
3652211
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682304%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
PubMed publication ID
23682304
1 reference
stated in
Europe PubMed Central
PMC publication ID
3652211
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23682304%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
